Home・Aandelen Lijst・Compugen Ltd

Compugen Ltd

Gesloten

2.6 -5.11

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

2.58

Max

2.62

Belangrijke statistieken
By Trading Economics
Inkomsten	663K -7M
Verkoop	426K 2.6M
K/W Sectorgemiddelde	6.816 57.366
EPS	-0.07
Winstmarge	-269.254
Werknemers	75
EBITDA	665K -7M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+92.31% upside

Dividenden
By Acuity
Volgende Winsten	9 nov 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	20M 245M
Vorige openingsprijs	7.71
Vorige sluitingsprijs	2.6

Compugen Ltd Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

30 aug 2026, 23:53 UTC

EUR/AUD is trading slightly higher in after-market hours, continuing its performance since Friday's close, though it remains near the lower end of its one-month range.

30 aug 2026, 23:53 UTC

Correlated Moves

Gold/AUD is lower amid cautious sentiment following Barclays' warning of a potential commodity shock due to adverse weather and underinvestment in production.

30 aug 2026, 23:53 UTC

Correlated Moves

Silver Ounce vs Euro is trading lower amid a broader decline in gold prices. Market sentiment is impacted by a Barclays report on potential commodity shocks.

30 aug 2026, 23:51 UTC

Correlated Moves

The S&P 500 Index is lower amid broader market trends and cautious investor sentiment following Barclays' forecasts of a potential commodity shock.

30 aug 2026, 23:51 UTC

Ethereum Drops 2.5% Amid Tech Stock Sell-Off and Economic Indicators, While Commodity Shock Looms from El Niño and Geopolitical Tensions Persist.

30 aug 2026, 23:51 UTC

Cryptocurrency Markets Decline Amid Geopolitical Tensions and Commodity Shock Warnings, with Key Economic Data Releases Ahead.

30 aug 2026, 23:51 UTC

Cryptocurrency markets decline as hedge funds sell tech stocks, while looming commodity shocks and geopolitical tensions raise inflation concerns ahead of key U.S. and Canadian labor data releases.

30 aug 2026, 23:51 UTC

Cryptocurrency markets decline as hedge funds sell tech stocks; Japan's economic indicators reveal consumer spending trends amid global uncertainties, while Barclays warns of a commodity shock from El Niño.

30 aug 2026, 23:51 UTC

Brazil's S&P Global Services PMI set for release on September 3, with analysts wary of further contraction following August's drop to 49.7 amid rising costs and political uncertainties.

30 aug 2026, 23:51 UTC

Australia's Building Permits Expected to Decline by 4.8% in July Amidst Economic Pressures and Market Volatility

30 aug 2026, 23:51 UTC

EUR/DKK remains effectively unchanged in after-market trading, showing unusual stability within a narrow band around its one-month trading range midpoint.

30 aug 2026, 23:51 UTC

Correlated Moves

Gold Ounce vs Euro is trading lower, continuing a five-session decline, influenced by falling Silver and cautious sentiment amid forecasts of a commodity shock.

30 aug 2026, 23:51 UTC

News

Bitcoin is trading lower today, despite earlier gains and social media discussions about Steak 'n Shake's Bitcoin initiative and potential AI investor interest.

30 aug 2026, 23:51 UTC

Bitcoin is trading lower during Sunday’s session amid heightened volatility. The price remains above its 20-day moving average and near its one-month range.

30 aug 2026, 23:42 UTC

Correlated Moves

The Nasdaq 100 Index is lower during Sunday’s session, reflecting broader market caution amid concerns over potential commodity shocks and adverse weather patterns.

30 aug 2026, 23:41 UTC

Japan's Industrial Production Expected to Decline in July Amid Global Economic Concerns and Commodity Supply Chain Disruptions.

30 aug 2026, 23:41 UTC

U.S. Unemployment Rate Release on September 4, 2026 Expected at 4.2%, Amid Cautious Optimism and Potential Fed Policy Implications

30 aug 2026, 23:41 UTC

US Average Hourly Earnings Expected to Rise 0.2% Amid Cautious Market Sentiment on Wage Growth and Inflation Concerns

30 aug 2026, 23:41 UTC

Labor Force Participation Rate in the U.S. Declines to 61.4%, Raising Concerns Ahead of September 2026 Data Release

30 aug 2026, 23:41 UTC

Investors Anticipate Key U.S. Average Hourly Earnings Data Amid Rising Inflation Concerns Ahead of September 4 Release

30 aug 2026, 23:41 UTC

US Non-Farm Payrolls Expected to Rise by Only 45K Jobs in August Amid Growing Employment Concerns

30 aug 2026, 23:41 UTC

Canada's Unemployment Rate Expected to Decrease Slightly to 6.4% Amidst Economic Challenges and Improved Employment Figures

30 aug 2026, 23:41 UTC

Canada's Labor Force Participation Rate Release on September 4, 2026, May Reflect Employment Dynamics Amid Housing Initiatives.

30 aug 2026, 23:41 UTC

Canada's Employment Change Forecast for August 2026 Predicts +15.8K Jobs Amid Positive Labor Market Sentiment Following July's Surprising Gain of +75.1K Positions

30 aug 2026, 23:41 UTC

Canada's Full-Time Employment Change Report Set for Release on September 4, Amid Economic Concerns and Political Developments.

30 aug 2026, 23:41 UTC

Canada's Part-Time Employment Change Report Set for September 4, 2026, Amid Cautious Optimism in Labor Market Dynamics.

30 aug 2026, 23:31 UTC

Correlated Moves

Avalanche is trading lower amid broader market sentiment, reflecting volatility. The asset remains above its 20-day moving average despite today's decline.

30 aug 2026, 23:31 UTC

Terra is trading lower today amid ongoing volatility and remains below its 20-day moving average, reflecting a decline since Saturday's session.

30 aug 2026, 23:31 UTC

Japan's Retail Sales Expected to Rise 0.03% YoY in July Amid Cautious Economic Sentiment and Weak Bond Market Performance

30 aug 2026, 23:31 UTC

Correlated Moves

XRP is declining during Sunday’s session amid notable volatility, aligning with a drop in Bitcoin. The asset remains above its 20-day moving average.

Peer Vergelijking

Prijswijziging

Compugen Ltd Prognose

Koersdoel

By TipRanks

92.31% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 5 USD 92.31%

Hoogste 6 USD

Laagste 4 USD

Gebaseerd op 2 Wall Street-analisten die 12-maands prijsdoelen bieden voor Compugen Ltd - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

2 ratings

Buy

Hold

Sell

Gebaseerd op 2 analisten die aandelenratings hebben gegeven aan Compugen Ltd - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.